CADTH Reimbursement Recommendation - Biologics for Plaque Psoriasis - Streamlined Drug Class Review
8 November 2023
biologics with anti-TNF and • CADTH assessed the quality of the Cochrane systematic review and NMA using the anti-IL-12/23 biologics? AMSTAR 2 and ISPOR network meta-analysis tools and found a high rating, increasing the confidence in the results. [...] With anti-IL-17 and anti-IL-23 biologics at the origin, FMEC deliberated on the location of anti-TNF and anti-IL-12/23 biologics on the decision plane. [...] Biologics for Plaque Psoriasis 8 / 10 Full Recommendation FMEC concluded that the current evidence supports the improved efficacy of anti-IL-17 and anti-IL-23 biologics compared to anti-TNF and anti-IL-12/23 biologics in the treatment of plaque psoriasis. [...] The Cochrane review was chosen as the basis of the clinical review as it is the most recent, comprehensive, and well-conducted NMA on the efficacy and safety of biologics for plaque psoriasis. [...] This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.